DMPI DelMar Pharmaceuticals Inc.

2.52
+0.45  (+22%)
Previous Close 2.07
Open 2.15
Price To Book -1.37
Market Cap 6683136
Shares 2,652,038
Volume 248,785
Short Ratio
Av. Daily Volume 65,377

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to be completed around mid-2020.
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
Phase 2 enrolment to be completed around mid-2020.
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Latest News

  1. DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
  2. DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results
  3. DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
  4. DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split
  5. DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
  6. DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
  7. DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
  8. DelMar Pharmaceuticals, Inc. to Host Earnings Call
  9. DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results
  10. DelMar Pharmaceuticals Receives Nasdaq Listing Extension
  11. Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals — Fundamental Analysis, Key Performance Indications
  12. DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
  13. DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
  14. Treat Aurora Cannabis Stock Normally at Your Own Peril
  15. Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)?
  16. DelMar Announces Further Validation of the Mechanism of Action of VAL-083
  17. DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
  18. DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor
  19. DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM